pacibekitug

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
pacibekitug

GtoPdb Ligand ID: 14206

Synonyms: PF 4236921 | PF-4236921 | PF04236921 | TOUR-006 | TOUR006

Compound class: Antibody

Comment: Pacibekitug (TOUR006; formerly PF-04236921) is a fully human IgG2 anti-IL-6 monoclonal antibody. It binds to a neutralises IL-6 activity. The peptides comprising pacibekitug are claimed in patent WO2009155180A1, and comprise the clone described as 9C8 N68T T83S therein [3].

References
1. Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux P, Leong RW, Comer GM et al.. (2019) Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). Gut, 68 (1): 40-48. [PMID:29247068]
2. Li C, Shoji S, Beebe J. (2018) Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease. Br J Clin Pharmacol, 84 (9): 2059-2074. [PMID:29776017]
3. Rajpal A, Devalaraja M, Toy K, Yang L, Huang H, Zhang JZ, Dexaux BD, Passmore DB. (2009) Antibodies to il-6 and their uses. Patent number: WO2009155180A1. Assignee: Medarex, Inc., Pfizer Inc.. Priority date: 10/06/2009. Publication date: 23/12/2009.
4. Wallace DJ, Strand V, Merrill JT, Popa S, Spindler AJ, Eimon A, Petri M, Smolen JS, Wajdula J, Christensen J et al.. (2017) Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis, 76 (3): 534-542. [PMID:27672124]

References

1. Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux P, Leong RW, Comer GM et al.. (2019)
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II).
Gut, 68 (1): 40-48. [PMID:29247068]

2. Li C, Shoji S, Beebe J. (2018)
Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease.
Br J Clin Pharmacol, 84 (9): 2059-2074. [PMID:29776017]

3. Rajpal A, Devalaraja M, Toy K, Yang L, Huang H, Zhang JZ, Dexaux BD, Passmore DB. (2009)
Antibodies to il-6 and their uses.
Patent number: WO2009155180A1. Assignee: Medarex, Inc., Pfizer Inc.. Priority date: 10/06/2009. Publication date: 23/12/2009.

4. Wallace DJ, Strand V, Merrill JT, Popa S, Spindler AJ, Eimon A, Petri M, Smolen JS, Wajdula J, Christensen J et al.. (2017)
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.
Ann Rheum Dis, 76 (3): 534-542. [PMID:27672124]